Peter H. O'Donnell, MD - UChicago Medicine

Dr. Peter O'Donnell, MD

Claim this profile

University of Chicago

Studies Bladder Cancer
Studies Transitional Cell Carcinoma
7 reported clinical trials
14 drugs studied

Area of expertise

1Bladder Cancer
Peter O'Donnell, MD has run 4 trials for Bladder Cancer. Some of their research focus areas include:
Stage III
HER2 positive
Stage IV
2Transitional Cell Carcinoma
Peter O'Donnell, MD has run 3 trials for Transitional Cell Carcinoma. Some of their research focus areas include:
Stage III
HER2 positive
Stage IV

Affiliated Hospitals

Image of trial facility.
University Of Chicago
Image of trial facility.
University Of Chicago Medical Center

Clinical Trials Peter O'Donnell, MD is currently running

Image of trial facility.

Genetic Testing

for Pain Relief in Cancer

This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Recruiting1 award N/A1 criteria
Image of trial facility.

Genetic Testing

for Surgery

The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago. At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS). Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients. There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).
Recruiting1 award N/A

More about Peter O'Donnell, MD

Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Peter O'Donnell, MD has experience with
  • Pharmacogenomic (PGx) Testing
  • Blood Test For Genetic Testing
  • Drug-genetic Profile
  • Routine Elective Surgery
  • Availability Of Clinical Decision Support Based On Pharmacogenomic Results
  • Pharmacogenomics (PGx) Testing And Genomics Prescribing Information (GPS)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Peter O'Donnell, MD specialize in?
Is Peter O'Donnell, MD currently recruiting for clinical trials?
Are there any treatments that Peter O'Donnell, MD has studied deeply?
What is the best way to schedule an appointment with Peter O'Donnell, MD?
What is the office address of Peter O'Donnell, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security